Mangoceuticals (MGRX) Stock Forecast & Analyst Ratings

Postmarket Movers: After-Hours Gainers and Decliners

Mangoceuticals Closes Registered Direct Offering Priced at 74% Premium to Recent Market Close

Mangoceuticals Closes Registered Direct Offering Following $2.5M Strategic Investment Commitment In MangoRx IP Holdings To Support Intellectual Property Commercialization

Curious about the stocks that are showing activity after the closing bell on Tuesday?

Mangoceuticals (MGRX) Shares Fall 12% After Hours: Here's Why

Investors agreed to buy 25% of Mangoceuticals’ company holding antiviral patents for $2.5 million.

Mangoceuticals Inc.’s Merger Partner, Nuclea Energy, Inc., Enters into Definitive Agreement to Acquire Moltex Energy’s Advanced Nuclear Technology Assets

Mangoceuticals’ Merger Partner, Nuclea Energy (“Nuclea”), Executes MOU with Utah Office of Energy Development

Mangoceuticals (MGRX) Stock Jumps Over 49% After Hours: Here's Why

Mangoceuticals Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement and Comments on Nuclea Energy Business Combination

MGRX surges after Nuclea Energy reverse-merger deal reshapes company story

Nuclea Energy Enters Definitive Business Combination Agreement with Mangoceuticals, Establishing a Path to a Nasdaq Public Listing to Advance the Morpheus Microreactor

Mangoceuticals Announces Business Combination Agreement with Nuclea Energy Inc. to Advance Next-Generation Nuclear Microreactor Technology

Mangoceuticals Announces Lawsuit Seeking Damages Exceeding $73 Million Against Former Technology Consulting and Software Development Firm, Clarity Ventures, Inc.